Conestoga Capital Advisors LLC Has $60.10 Million Holdings in Azenta, Inc. $AZTA

Conestoga Capital Advisors LLC grew its holdings in shares of Azenta, Inc. (NASDAQ:AZTA) by 116.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,844,546 shares of the company’s stock after buying an additional 1,528,145 shares during the period. Conestoga Capital Advisors LLC owned approximately 0.06% of Azenta worth $60,105,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd increased its stake in shares of Azenta by 2,067.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after acquiring an additional 765 shares in the last quarter. Assetmark Inc. grew its holdings in Azenta by 54.1% in the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after purchasing an additional 292 shares during the period. Osaic Holdings Inc. grew its holdings in Azenta by 44.9% in the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after purchasing an additional 385 shares during the period. Rockefeller Capital Management L.P. increased its stake in Azenta by 98.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after purchasing an additional 689 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in shares of Azenta by 141.2% during the fourth quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after purchasing an additional 928 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Trading Up 2.6%

AZTA opened at $26.19 on Thursday. The company’s fifty day moving average price is $22.13 and its two-hundred day moving average price is $27.04. Azenta, Inc. has a 1-year low of $15.93 and a 1-year high of $41.73. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -6.61 and a beta of 1.37.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The business had revenue of $144.79 million for the quarter, compared to analyst estimates of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.01 earnings per share.

Wall Street Analyst Weigh In

AZTA has been the topic of a number of research analyst reports. Needham & Company LLC cut their price objective on shares of Azenta from $44.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings downgraded Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Azenta has an average rating of “Hold” and an average target price of $39.50.

About Azenta

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end?to?end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next?generation sequencing (NGS), DNA synthesis, and molecular biology services.